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Background: The frequency of preterm labour has risen over the last few years. Hence, there is growing interest in
the identification of markers that may facilitate prediction and prevention of premature birth complications. Here,
we studied the association of the number of circulating stem cell populations with the incidence of complications
typical of prematurity.
Methods: The study groups consisted of 90 preterm (23–36 weeks of gestational age) and 52 full-term
(37–41 weeks) infants. Non-hematopoietic stem cells (non-HSCs; CD45-lin-CD184+), enriched in very small
embryonic-like stem cells (VSELs), expressing pluripotent (Oct-4, Nanog), early neural (β-III-tubulin), and
oligodendrocyte lineage (Olig-1) genes as well as hematopoietic stem cells (HSCs; CD45+lin-CD184+), and circulating
stem/progenitor cells (CSPCs; CD133+CD34+; CD133-CD34+) in association with characteristics of prematurity and
preterm morbidity were analyzed in cord blood (CB) and peripheral blood (PB) until the sixth week after delivery.
Phenotype analysis was performed using flow cytometry methods. Clonogenic assays suitable for detection of
human hematopoietic progenitor cells were also applied. The quantitative parameters were compared between
groups by the Mann–Whitney test and between time points by the Friedman test. Fisher’s exact test was used for
qualitative variables.
Results: We found that the number of CB non-HSCs/VSELs is inversely associated with the birth weight of preterm
infants. More notably, a high number of CB HSCs is strongly associated with a lower risk of prematurity
complications including intraventricular hemorrhage, respiratory distress syndrome, infections, and anemia. The
number of HSCs remains stable for the first six weeks of postnatal life. Besides, the number of CSPCs in CB is
significantly higher in preterm infants than in full-term neonates (p < 0.0001) and extensively decreases in preterm
babies during next six weeks after birth. Finally, the growth of burst-forming unit of erythrocytes (BFU-E) and
colony-forming units of granulocyte-macrophage (CFU-GM) obtained from CB of premature neonates is higher than
those obtained from CB of full-term infants and strongly correlates with the number of CB-derived CSPCs.
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Conclusion: We conclude that CB HSCs are markedly associated with the development of premature birth
complications. Thus, HSCs ought to be considered as the potential target for further research as they may be
relevant for predicting and controlling the morbidity of premature infants. Moreover, the observed levels of
non-HSCs/VSELs circulating in CB are inversely associated with the birth weight of preterm infants, suggesting
non-HSCs/VSELs might be involved in the maturation of fetal organism.
Keywords: Hematopoietic stem cells, Very small embryonic-like stem cells, Peripheral blood circulating stem cells,
Blood testing, Complications of prematurity, Premature infantsBackground
The premature birth of infants is an important issue fa-
cing perinatologists and pediatricians, mostly in devel-
oped countries, where the scale of preterm births is
constantly increasing [1]. Independent of the cause of
preterm labour, premature infants of low birth weight
(BW) reveal a high risk of complications, including brain
injury (e.g. intraventricular hemorrhage; IVH), retinop-
athy of prematurity (ROP), neonatal respiratory distress
syndrome (RDS), bronchopulmonary dysplasia (BPD),
necrotizing enterocolitis (NEC), and anemia, resulting in
psychomotor disability. Development and progression of
these serious complications may result from hypoxia, in-
fection, metabolic disorders, and a general lack of adap-
tation to the extrauterine environment [2].
Survival of premature infants has significantly improved
in recent years due to better care, nutrition, ventilation
strategies, and behavioral adaptations [3]. However, mor-
tality and morbidity rates are still relatively high in this
population [3]. Infants of the same gestational age (GA)
living in intrauterine conditions gradually mature to extra-
uterine life and usually do not suffer from organ damage
or dysfunctions. Advances in research on stem cell biology
have provided a chance for elucidation of the role of these
cells in normal human development as well as in patho-
physiological conditions. Evidence has accumulated indi-
cating that a portion of stem/progenitor cells (SPCs)
circulates in the peripheral blood to maintain a balance
between SPCs populations in various anatomic areas of
the living organism [4]. The number of these cells
increases during organ and tissue injury, e.g. heart infarct,
stroke, heavy burns, or liver or skeletal muscle damage
[4-7]. Recent reports suggest that stem cells may play a
role in the process of the endogenous regeneration of
damaged organs [8].
In light of these issues, we investigated the potential
association between the number of circulating stem
and progenitor cell populations and levels of the che-
mokine regulating SPCs migration with the incidence
of complications typical of prematurity in a prospective
study. To date, no study has been performed to evalu-
ate circulating SPCs numbers in premature infants
within the first six weeks of extrauterine life. Thisstudy identified the kinetics of representative and
highly selected SPCs populations circulating in the per-
ipheral blood of premature and full-term babies at dif-
ferent time points in order to provide data showing a
possible association with prematurity complications.
Based on recent reports, the surface phenotypes for
non-HSCs and HSCs were defined in our study as
CD45-lin-CD184+ and CD45+lin-CD184+ cells, respect-
ively [5,6]. The former cell population phenotypically cor-
responds to very small embryonic-like stem cells
(VSELs), that express markers of pluripotent SCs (e.g.,
Oct4, Nanog, and SSEA-4) [9]. We also analyzed circulat-
ing stem/progenitor cells defined as CD133+CD34+ and
CD133-CD34+ cells in order to investigate more differen-
tiated blood cells. Finally, the clonogenic proliferative cap-
acity of CB-derived hematopoietic progenitor cells from
premature and full-term neonates was evaluated.Methods
Characteristics of study groups
Subjects were recruited from patients of the Pomeranian
Medical University in Szczecin, born between October
2007 and May 2010. We enrolled 90 preterm infants born
at less than 37 weeks (wks) (23–36 wks) of gestational
age and 52 healthy full-term infants (≥37 wks) as controls.
The following exclusion criteria were applied: major con-
genital or chromosomal abnormalities, cyanotic heart
defects, chronic intrauterine hypoxia (defined as growth
retardation or pathologies of placental perfusion), transfu-
sion in the operating theatre, exchange transfusion, or
missing parental consent. Each child’s birth weight, sex,
GA, Apgar scores, and neonatal clinical course were
documented during the infants’ hospitalization and for
the outpatient controls during six weeks of prospective
observations after birth.
In each case, intraventricular hemorrhage (IVH) was
diagnosed by ultrasonography (usg). Brain Doppler usg
examination of the anterior cerebral artery and color
cerebral function monitoring were performed for each
patient with IVH.
Retinopathy of prematurity (ROP) was diagnosed and
classified according to the International Classification of
Retinopathy of Prematurity (International Committee)
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retinal neovascularisation (stage 3 or more).
Respiratory distress syndrome (RDS) was diagnosed
based on the physical examination, blood gas tests, and
chest X-ray analysis using Bomsel’s classification [11] fol-
lowed by echocardiography. Additionally, microbial tests
were performed to rule out infection and sepsis.
Bronchopulmonary dysplasia (BPD) was diagnosed
based on requirement of oxygen supplementation at
36 weeks postmenstrual age (PMA) and abnormal find-
ings on chest radiography [12-14].
Necrotizing enterocolitis (NEC) was diagnosed in neo-
nates who fulfilled at least stage II (definite NEC) of
modified Bell’s criteria [15].
Anemia necessitating red blood cell transfusion was
considered in spontaneously breathing infants (regardless
of GA) if the hematocrit level fell to <40%, 35%, or 30%
in the first, second, or third and fourth week of life, re-
spectively. In infants older than 4 weeks, anemia necessi-
tating transfusion was considered when the hematocrit
level fell to <25%. In infants who were being ventilated or
had an acute illness, the hematocrit threshold for trans-
fusion was five percent higher than that mentioned above
[16].
Neonatal infection was diagnosed based on a
physician-defined examination that included serum C-
reactive protein (CRP) (≥15 mg/L) and procalcitonin
(PCT) (>0.5 ng/mL) analyses and blood cultures. Since
positive blood cultures were not obtained in all cases
of clinically diagnosed infections, they are treated as
“suspected infections”. Within at least one week before
blood collection, the enrolled patients were free of
blood transfusions.
The control group consisted of full-term babies with
no systemic, inherited or metabolic disorders. The study
adhered to the tenets of the Declaration of Helsinki and
approval was obtained from the Local Research Ethics
Committee of the Pomeranian Medical University in
Szczecin. The parents gave written informed consent for
their child’s involvement.Sample collection
Venous blood samples (10 mL of CB and ~1.5 mL of
PB) were collected in EDTA tubes at the moment of de-
livery as well as at the end of the second and sixth week
after delivery. An aliquot of each sample was centrifuged
(2000 rpm, 4°C, 10 min) and the plasma was stored at
−80°C until assayed for SDF-1. The rest of the sample
was used for flow cytometry, immunofluorescence and
qRT-PCR. For the study of the kinetics of blood cell
populations, we analysed data in subgroups of 13 pre-
term (GA: 33.2 ± 3.1 wks, BW: 2352 ± 778 g) and 18 full-
term infants (GA: 38.9 ± 1.2 wks, BW: 3462 ± 338 g) forwhom all three blood samples (CB, PB from the second
and sixth week) were available.Flow cytometry
Whole CB or PB samples were lysed in BD PharmLyse
Lysing Solution (BD Bioscences, San Jose, CA, USA) for
15 min at room temperature (RT) in the dark. The
obtained suspension of CB or PB nucleated cells (NCs)
was subjected to immunostaining procedures with mur-
ine anti-human monoclonal antibodies, as described pre-
viously [5,17]. For linage markers we used antibodies
against: CD2 clone RPA-2.10, CD3 clone SK7, CD14
clone MϕP9, CD16 clone 3 G8, CD19 clone HIB19,
CD24 clone ML5, CD56 clone NCAM16.2, CD66b clone
G10F5, CD235a clone GA-R2 (all from BD Bioscences,
San Jose, CA, USA). Flow cytometric analyses were per-
formed using the LSRII instrument (BD, Biosciences, San
Jose, CA, USA). Data were acquired with Cell Quest soft-
ware (BD Biosciences, San Jose, CA, USA). Only freshly
isolated cells were stained for flow cytometry and sam-
ples were run in the cytometer following the standard
cleaning procedure. At least 105 CB-derived and PB-
derived cells with the appropriate ratio of forward scatter
to side scatter were acquired, and all NCs were gated. In
each case of CB, the collection of NCs was further
extended to 2×106 events per sample in order to increase
enumeration rate of analyzed rare subpopulations of SCs,
and thus augment the predictive value of the obtained
results. The relative number of cells in each population
was expressed as a percentage of the analyzed NCs after
resting the number of total events found in the corre-
sponding negative isotype control gate. The gating strat-
egy for the analysis and sorting by FACS of different SC
populations in this study is presented in Figure 1.Isolation and immunofluorescence of cord/peripheral
blood-derived SCs
The population of CD45-lin-CD184+ cells was sorted by
multiparameter, live sterile cell sorting (BD FACSAriaIIu
Cell-Sorting System, BD Biosciences, San Jose, CA,
USA). Cell staining for all of the antigens was performed
as described previously [17]. The sorted cells were per-
meabilized (0.1% Triton X-100, 10 min) and stained for
β-III-tubulin, Nanog and Oct-4 antigens with anti-
human monoclonal antibodies (Abcam, Cambridge, UK)
for 1 h at RT, followed by incubation with a secondary
antibody conjugated to Texas RedW (Vector Labs,
Burlingame, CA, USA). The cells were subsequently
fixed (3.7% paraformaldehyde) and their nuclei were
stained with DAPI (Invitrogen, Paisley, UK). For fluores-
cence images, the BD Biosciences Pathway 855 bioima-






































































Figure 1 (See legend on next page.)
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Figure 1 A representative study of gating strategy for analyzing/sorting of non-HSCs/VSELs, HSCs, and CSPCs circulating in newborn
PB by FACS. Each colored gate illustrates a population of cells which expresses selected surface proteins. Panel A: Cytofluorimetric analysis of
non-HSCs and HSC: CD184+lin- cells were gated from a total fraction of immunofluorescence-stained nucleated cells from the PB of preterm
and full term infants, then those cells from region R1 were further analyzed for CD45 expression; Panel B: Cytofluorimetric analysis of CSPCs
(CD133+CD34+ and CD133-CD34+): CD34+ cells were gated from a total fraction of immunofluorescence-stained nucleated cells from the PB
of preterm and full term infants, then those cells from region R2 were further analyzed for CD133 expression.
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(qRT-PCR)
To analyze the mRNA levels for pluripotent (Oct-4,
Nanog), early neural markers (β-III-tubulin), and oligo-
dendrocyte lineage genes (Olig-1), total mRNA was
isolated from CB cells using the RNeasy Mini Kit
(Qiagen GmbH). Subsequently, the mRNA was reverse-
transcribed using the First Strand cDNA Synthesis Kit
(Fermentas International Inc., Burlington, ON, Canada).
A quantitative assessment of mRNA levels was per-
formed by using a Bio-Rad CFX96 Real-Time PCR De-
tection System (Bio-Rad Inc., Philadelphia, PA, USA). A
15 μL reaction mixture containing 7.5 μL iQ SYBR
Green SuperMix (Bio-Rad Inc., Philadelphia, PA, USA) and
10 ng of complementary (c) DNA template, and 0.9 μM of
forward and reverse primers for Oct-4, Nanog, β-III-tubu-
lin, Olig-1 and β2-microglobulin (BMG) was used. The
cDNA was amplified under the following conditions: 1 cycle
at 50°C for 2 min and at 95°C for 10 min, followed by
40 cycles at 95°C for 15 s and at 60°C for 1 min. Relative
quantification of mRNA expression was calculated by the
comparative Ct method. The relative quantization value of
the target, normalized to an endogenous control gene
(BMG) and relative to a calibrator, was expressed as 2-ΔΔCt,
where ΔCt = Ct of the target genes - Ct of the endogenous
control gene, and ΔΔCt = ΔCt of the sample - ΔCt of the
calibrator.
Cell cultures
The CD34-positive cells (2 × 104) were obtained by
immunomagnetic beads from the CB of 44 preterm (GA:
33.3 ± 3.2 wks, BW: 2239 ± 640 g) and 24 full-term
infants (GA: 39.2 ± 1.1 wks, BW: 3485 ± 404 g) using
CD34 MicroBead Kit (Miltenyi Biotec Auburn, CA,
USA) according to the manufacturer’s instructions. Next,
the isolated CD34+ cells were resuspended in 0.4 mL of
Iscove’s Modified Dulbecco’s Medium and mixed with
1.8 mL of the methylcellulose medium MethoCult HCC-
4230 (StemCell Technologies Inc., Vancouver, BC,
Canada) supplemented with L-glutamine and antibiotics.
The appropriate recombinant human growth factors
were added to the mixture as described previously [18].
The colonies were counted using an inverted microscope
on day 11 for BFU-E and on day 14 for CFU-GM. Cul-
tures developed from each blood sample were analyzed
in quadruplicate.Plasma concentration of SDF-1
Levels of stromal-derived factor-1 (SDF-1) were mea-
sured using the commercially available high-sensitivity
enzyme-linked immunosorbent assay (ELISA) Quanti-
kine human immunoassay kits (R&D Systems, McKinley
Place, MN, USA) according to the manufacturer’s proto-
col. The absorbance was read at 450 nm using an ELX
808 IU automated Microplate Reader (Bio-Tek Instru-
ments Inc, Winooski, VT, USA). The results were ana-
lyzed using a quadratic loglog curve fit.
Statistical methods
Differences in the values of the quantitative parameters
were compared between groups by the Mann–Whitney
test and between time points by the Friedman test.
Fisher’s exact test was used for qualitative variables.
Correlations between parameters were assessed using
Spearman’s rank correlation coefficient (Rs). Univariate
and multivariate logistic regression were performed to
check the associations between selected parameters
and prematurity complications. A p value of <0.05 was
considered statistically significant.
Results
Characteristics of the clinical parameters
The characteristics of the clinical parameters, including
maternal data and the incidence of complications in pre-
term and full-term infants are summarized in Table 1.
The mean difference in gestational age at birth between
the preterm and full-term groups of infants was
6.3 weeks. Consequently, preterm infants had a signifi-
cantly lower mean birth weight (2145 g vs. 3530 g) and
Apgar score at 1 min (7.8 vs. 9.3). Both groups were
matched for gender. The most frequent complications
(>15% incidence) diagnosed in preterm infants during
the six week prospective observation period were infec-
tions, IVH, RDS and anemia necessitating red blood cell
transfusion. Out of the preterm infants, 42% had at least
one of the seven complications analysed (Table 1). A
subgroup of 13 infants with extremely low gestational
age at birth (GA: ≤30 wks, mean ± SD: 26.8 ± 2.2 wks,
BW: 1141 ± 370 g) had particularly high incidence of the
complications (IVH-77%, RDS-77%, BPD-54%, ROP-
38%, NEC-15%, infection-85%, anemia-100%). We did
not observed the infant mortality during the whole
period of the study.
Table 1 Characteristics of clinical parameters, maternal














33.0 ± 3.0 (34) 39.3 ± 1.2 (39) <0.0001
Body weight at
birth [g]
2145 ± 628 (2175) 3530 ± 387 (3595) <0.0001
Male gender 56 (62%) 24 (46%) 0.079
Cesarean section 35 (39%) 7 (14%) 0.0012
Apgar score at 1 min 7.8 ± 2.1 (8) 9.3 ± 1.3 (10) <0.0001
IVH 19 (21%) 1 (2%) 0.0009
RDS 18 (20%) 0 (0%) 0.0002
BPD 7 (8%) 0 (0%) 0.048
ROP (stage 3 or more) 6 (7%) 0 (0%) 0.086
NEC (stage II or more) 3 (3%) 0 (0%) 0.30
Suspected infection 30 (33%) 1 (2%) <0.0001
Anemia 16 (18%) 0 (0%) 0.0006
Any complication 38 (42%) 2 (4%) <0.0001
Antenatal steroids 16 (18%) 0 (0%) 0.0006
Pre-eclampsia 4 (4%) 0 (0%) 0.30
Diabetes mellitus 0 (0%) 1 (2%) 0.37
Chorioamnionitis 6 (7%) 0 (0%) 0.086
Premature rupture
of membranes
26 (29%) 8 (15%) 0.10
a Mann–Whitney test for quantitative variables and Fisher’s exact test for
qualitative variables.
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associated with the birth weight of preterm infants
To analyze distinct stem cell types we selected CD45-
lin-CD184+ and CD45+lin-CD184+ phenotypes that rep-
resent primitive, non-hematopoietic (non-HSC) and
hematopoietic (HSC) stem cells, respectively [5,6,17].
Based on our previous reports, and in order to verify
whether or not the population of non-HSCs comprise
very small embryonic-like stem cells (VSELs), thus we
evaluated in parallel the expression of markers common
to pluripotent or undifferentiated cells by immunocyto-
fluorescence and qRT-PCR in those cells. Hence, we
sorted a population of non-HSCs from among the CB
nucleated cells, and showed that these early cells
expressed Oct-4, Nanog, and β-III-tubulin at the pro-
tein level, as revealed by immunofluorescence staining
(Figure 2). Furthermore, in CB cells we noticed signifi-
cant positive correlations between the number of non-
HSCs and the expression of Oct-4 (Rs = +0.89,
p = 0.019), Nanog (Rs = +0.89, p = 0.019), and β-III-
tubulin (Rs = +0.90, p = 0.037) at the mRNA level, asrevealed by qRT-PCR, whereas a correlation with
Olig-1 expression did not reach statistical signifi-
cance (Rs = +0.60, p = 0.21). No such positive correla-
tions were found for HSC population. We therefore
concluded that non-HSCs are the most primitive cells,
enriched in VSEL SCs, from among the populations
examined in our study, whereas HSCs could be
defined as more differentiated cells. We used flow
cytometry in order to estimate the number of exam-
ined SC populations in the CB of preterm and full-
term infants. We found no significant differences in
the number of CD45–lin–CD184+ or CD45+lin–CD184+
cells between the preterm and full-term infants (Table 2).
There were no associations between the number of the
above cells and the infants’ gender, type of delivery
(physiological vs. cesarean section), age of gestation, or
neonatal complications. However, in preterm infants we
found a significant negative correlation between BW and
the number of circulating non-HSCs/VSELs (Rs =−0.23,
p = 0.033), although there was no correlation with the
number of HSCs (Rs = +0.08, p = 0.44). These data
revealed for the first time that the number of circulating
non-HSCs/VSELs is inversely associated with the birth
weight of preterm infants.
The high number of circulating CB HSCs is strongly
associated with a lower risk of IVH, RDS, infections,
and anemia
To elucidate whether or not the concentration of SCs
circulating in CB reveals relationship with the develop-
ment of prematurity complications, we performed an ex-
tensive statistical analysis. As shown in Table 3, in
newborns who developed IVH, RDS, infection, anemia,
or any of the seven analyzed prematurity complications
(in this subgroup, distinguished for statistical purposes,
we grouped together preterm infants with at least one of
the seven analyzed complications: IVH, RDS, BPD, ROP,
NEC, infection, anemia) a significantly lower number of
circulating CD45+lin-CD184+ cells was observed in com-
parison to infants without these complications. The inci-
dence of any complication was significantly lower in the
42 preterm infants with the presence of at least 0.0010%
HSCs in CB compared to 48 with <0.0010% HSCs (11/
42 = 26% vs. 27/48 = 56%, p = 0.0054, OR= 0.28, 95%
CI = 0.11-0.68). Of note, there was no association be-
tween the number of CD45-lin-CD184+ CB cells and any
of the examined complications. Additionally, to check
whether or not the association between the number of
CD45+lin-CD184+ CB cells with the most frequent pre-
maturity complications was independent from the other
clinical factors, we performed logistic regression analysis
(Table 4). Multivariate models with gestational age,
type of delivery, Apgar score at 1st minute, and the pres-
ence of at least 0.0010% HSCs in CB as independent
Figure 2 Immunocytofluorescence of CB-derived non-HSCs. Individual images depict the expression of pluripotent/early neuronal
markers, CD184, as well as nuclei in non-HSCs. Merged images show coexpression of β-III-tubulin (panel A), Oct-4 (panel B), Nanog (panel C),
and CD184, together with nuclei. Pseudocolors are assigned to each staining as follows: anti-β-III-tubulin, -Oct-4, and -Nanog – green,
anti-CD184 – red, nuclei - blue. The cells were captured with × 40 objective magnification. The expression of each antigen was examined in
cells in six independent experiments. Representative data are shown.
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associated with a significantly lower risk of IVH, RDS,
and infections, with borderline statistical significance
(p = 0.092) for anemia. The association was also statisti-
cally significant for the development of any of the seven
analyzed prematurity complications (OR= 0.28, 95% CI =
0.09-0.86, p = 0.024). Of note, in all multivariate models,
the higher GA was associated with a lower risk of com-
plications (OR from 0.25 to 0.68 per week). These results
clearly indicate that the number of HSCs circulating in
CB is an independent predictor inversely associated with
the development of premature birth complications.Table 2 Cord blood stem and progenitor cell populations and
infants
Parameter Preterm infants
n Mean ± SD (Median)
CD45-lin-CD184+ [%] 90 0.0294 ± 0.0319 (0.0180)
CD45+lin-CD184+ [%] 90 0.0016 ± 0.0032 (0)
CD133+CD34+ [%] 90 0.349± 0.249 (0.313)
CD133-CD34+ [%] 90 0.111± 0.092 (0.087)
SDF-1 [pg/mL] 90 1642± 488 (1562)
a Mann–Whitney test; n – number of measurements.The population of circulating HSCs remains stable for the
first six weeks of human life
In order to study the kinetics of the changes in the num-
bers of stem cells circulating in PB after birth, we pro-
spectively analyzed the cell populations in the second
and sixth week of extrauterine life, both in preterm and
full-term infants. Figure 3 presents the numbers of two
different blood SC populations (counted in CB at birth as
well as in PB two and six weeks after birth) in preterm
and full-term infants. We found no significant changes in
the number of non-HSCs/VSELs and HSCs in CB com-
pared to PB. However, two weeks after birth the numberSDF-1 plasma concentrations in preterm and full-term
Full-term infants p a
n Mean ± SD (Median)
52 0.0209 ± 0.0201 (0.0135) 0.068
52 0.0022 ± 0.0040 (0) 0.92
52 0.142± 0.088 (0.139) <0.0001
52 0.037± 0.025 (0.0305) <0.0001
52 1727± 552 (1662) 0.35
Table 3 Associations between prematurity complications and number of CB stem and progenitor cell populations in
preterm infants
Complication Cord blood cell
population
Complication absent [%] Complication present [%] p a
Mean ± SD (Median) Mean ± SD (Median)
IVH CD45–lin–CD184+ 0.0289 ± 0.0331 (0.0180) 0.0316 ± 0.0276 (0.0200) 0.41
CD45+lin–CD184+ 0.0020 ± 0.0035 (0.0010) 0.0004 ± 0.0008 (0) 0.014
CD133+CD34+ 0.342 ± 0.248 (0.306) 0.374 ± 0.258 (0.442) 0.52
CD133-CD34+ 0.100 ± 0.077 (0.087) 0.152 ± 0.126 (0.086) 0.26
RDS CD45–lin–CD184+ 0.0272 ± 0.0283 (0.0170) 0.0386 ± 0.0433 (0.0215) 0.13
CD45+lin–CD184+ 0.0020 ± 0.0034 (0.0010) 0.0003 ± 0.0006 (0) 0.0048
CD133+CD34+ 0.320 ± 0.238 (0.3053) 0.467 ± 0.265 (0.529) 0.027
CD133-CD34+ 0.095 ± 0.073 (0.083) 0.175 ± 0.128 (0.114) 0.019
BPD CD45–lin–CD184+ 0.0292 ± 0.0321 (0.0180) 0.0328 ± 0.0321 (0.0190) 0.76
CD45+lin–CD184+ 0.0017 ± 0.0033 (0) 0.0005 ± 0.0008 (0) 0.39
CD133+CD34+ 0.330 ± 0.244 (0.306) 0.570 ± 0.207 (0.544) 0.013
CD133-CD34+ 0.101 ± 0.080 (0.086) 0.238 ± 0.132 (0.248) 0.0074
ROP CD45–lin–CD184+ 0.0290 ± 0.0319 (0.0180) 0.0356 ± 0.0341 (0.0188) 0.68
CD45+lin–CD184+ 0.0017 ± 0.0033 (0) 0.0003 ± 0.0004 (0) 0.20
CD133+CD34+ 0.344 ± 0.251 (0.310) 0.424 ± 0.220 (0.510) 0.35
CD133-CD34+ 0.106 ± 0.085 (0.087) 0.186 ± 0.152 (0.162) 0.32
NEC CD45–lin–CD184+ 0.0298 ± 0.0324 (0.0180) 0.0180 ± 0.0046 (0.0190) 0.95
CD45+lin–CD184+ 0.0017 ± 0.0032 (0) 0 ± 0 (0) 0.12
CD133+CD34+ 0.338 ± 0.246 (0.310) 0.662 ± 0.014 (0.670) 0.015
CD133-CD34+ 0.108 ± 0.091 (0.086) 0.214 ± 0.032 (0.211) 0.025
Infection CD45–lin–CD184+ 0.0308 ± 0.0352 (0.0180) 0.0268 ± 0.0244 (0.0190) 0.96
CD45+lin–CD184+ 0.0020 ± 0.0036 (0.0010) 0.0010 ± 0.0021 (0) 0.034
CD133+CD34+ 0.345 ± 0.264 (0.307) 0.358 ± 0.220 (0.324) 0.60
CD133-CD34+ 0.105 ± 0.089 (0.085) 0.123 ± 0.098 (0.092) 0.43
Anemia CD45–lin–CD184+ 0.0298 ± 0.0333 (0.0180) 0.0276 ± 0.0252 (0.0195) 0.95
CD45+lin–CD184+ 0.0019 ± 0.0034 (0.0010) 0.0005 ± 0.0011 (0) 0.029
CD133+CD34+ 0.336 ± 0.247 (0.310) 0.409 ± 0.260 (0.464) 0.28
CD133-CD34+ 0.098 ± 0.077 (0.084) 0.175 ± 0.126 (0.152) 0.031
Any complication CD45–lin–CD184+ 0.0284 ± 0.0298 (0.0180) 0.0308 ± 0.0350 (0.0185) 0.86
CD45+lin–CD184+ 0.0021 ± 0.0038 (0.0010) 0.0010 ± 0.0019 (0) 0.014
CD133+CD34+ 0.341 ± 0.250 (0.307) 0.359 ± 0.251 (0.319) 0.71
CD133-CD34+ 0.099 ± 0.077 (0.085) 0.129 ± 0.107 (0.087) 0.30
a Mann–Whitney test.
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term than in full-term infants (p = 0.018), although the
difference was insignificant six weeks after birth
(p = 0.68). Interestingly, we also observed a correlation
between the number of HSCs in CB and in PB six weeks
after birth, both in preterm (Rs = +0.89, p < 0.0001) and
full-term infants (Rs = +0.66, p = 0.0028). This suggests
that the HSC population is stable in the blood of preterm
and full-term infants and that the number of these cells
in CB at birth is a strong predictor of the cell number in
PB six weeks later. This phenomenon may partly explain
the protective effect of CD45+lin-CD184+ cells against
prematurity complications (Table 4), because their lowpool in CB at birth is associated with a long-term HSC
deficit which lasts at least six weeks after delivery – the
period when most complications develop.
Since stem cell migration is mediated by chemokines
and other regulatory molecules, we studied changes in
plasma concentrations of SDF-1, the most important
chemotactic factor, critical for stem cell motility, homing,
and mobilization [19]. We found no significant differ-
ences in SDF-1 concentrations in CB between preterm
and full-term infants (Table 2). Moreover, SDF-1 levels in
CB were not significantly associated with preterm infant
gender, type of delivery, or any of the analyzed prematurity
complications, and it did not correlate with the number of
Table 4 Univariate and multivariate logistic regression models for the association of the presence of ≥0.0010% HSCs in




Complications IVH RDS Infections Anemia Any complication
Independent
variables
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
univariate HSCs≥ 0.0010% 0.23 (0.07-0.78) 0.017 0.17 (0.04-0.65) 0.0085 0.28 (0.11-0.73) 0.0088 0.21 (0.05-0.80) 0.021 0.28 (0.11-0.68) 0.0047
multivariate HSCs≥ 0.0010% 0.23 (0.05-0.997) 0.046 0.10 (0.01-0.86) 0.033 0.32 (0.10-1.01) 0.048 0.06 (0.002-1.67) 0.092 0.28 (0.09-0.86) 0.024
Gestational age
(wks)
0.68 (0.52-0.88) 0.0035 0.45 (0.30-0.68) 0.0002 0.65 (0.49-0.84) 0.0011 0.25 (0.10-0.61) 0.0021 0.54 (0.39-0.75) 0.0002
Cesarean section
(yes vs. no)
0.47 (0.12-1.94) 0.29 0.76 (0.14-4.13) 0.75 1.93 (0.63-5.93) 0.24 0.36 (0.03-4.59) 0.42 1.43 (0.46-4.40) 0.53
Apgar score at
1 min (points)
0.80 (0.56-1.16) 0.23 0.99 (0.63-1.57) 0.96 0.96 (0.69-1.32) 0.79 0.93 (0.51-1.69) 0.81 1.03 (0.74-1.43) 0.87
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preterm infants, the plasma level of SDF-1 was signifi-
cantly higher two weeks after delivery compared to cord
blood (p= 0.011), whereas the difference was insignificant
six weeks thereafter (p= 0.086). Furthermore, we noticed
a strong correlation between CB SDF-1 levels and the
number of non-HSCs/VSELs two weeks after delivery
(Rs =+0.86, p = 0.014); however, this was statistically in-
significant six weeks after delivery (Rs =+0.36, p = 0.43).
Together these results suggest that SDF-1 may influence
the circulating postnatal non-HSC/VSELs population in
preterm infants.
Premature infants contain a larger pool of progenitor
cells circulating in their cord blood compared to full-term
babies
To expand our study, we also measured the number of
more restricted circulating stem/progenitor populations
such as CD133+CD34+ and CD133-CD34+ cells that may
contribute to tissue homeostasis by replenishing the
lineage-specific hematopoietic cells. As shown in Table 2,
preterm babies revealed in CB significantly higher num-
bers of CD133+CD34+ and CD133-CD34+ CSPCs thanFigure 3 The number of CD45-lin-CD184+ (non-HSCs) and CD45+lin-CD
as well as in PB two and six weeks after birth in 13 preterm and 18 fu
full-term infants (Mann–Whitney test). No statistically significant changes wfull-term infants (p < 0.0001). We also took into consid-
eration the GA and evaluated whether or not this par-
ameter could determine the number of CSPCs in CB. As
revealed, a subgroup of 13 infants with extremely low
GA at birth (≤30 weeks) had an even higher number of
CD133-CD34+ cells than the remaining preterm infants
(0.193 ± 0.131 vs. 0.098 ± 0.076%, p = 0.015). Nonetheless,
no significant correlations between body weight at birth
and CD133+CD34+ (Rs =−0.02, p = 0.85) or CD133-
CD34+ cells (Rs =−0.09, p = 0.41) were found in preterm
infants.
Furthermore, we performed the clonogenic assays to ver-
ify whether or not the CD133+CD34+ and CD133-CD34+
CSPCs represent hematopoietic progenitors as similar
phenotype might involve also endothelial progenitors to
some extent [20]. Likewise, we found that the numbers of
clonogenic BFU-E and CFU-GM were significantly higher
in preterm infants compared to full-term infants (191± 91
vs. 78 ± 45, p < 0.0001 for BFU-E and 61± 34 vs. 33 ± 28,
p < 0.0001 for CFU-GM, Figure 4). What is more, in pre-
term infants both BFU-E and CFU-GM colony numbers
were strongly positively correlated with the number of
CD133+CD34+ and CD133-CD34+ CSPCs, regardless of184+ (HSCs) blood stem cell populations counted in CB at birth
ll-term infants. *p < 0.05 for comparison between preterm and
ere observed within each group (p > 0.15, Friedman test).
Table 5 Spearman rank correlation coefficients (Rs) for
the association between cord blood-derived stem and
progenitor cell populations and clonogenic potential in
preterm infants (n = 44)
Parameter BFU-E CFU-GM
Rs p Rs p
Gestational age −0.16 0.29 −0.09 0.57
CD45–lin–CD184+ −0.08 0.62 −0.05 0.74
CD45+lin–CD184+ −0.04 0.79 +0.18 0.24
CD133+CD34+ +0.67 <0.0001 +0.51 0.0005
CD133-CD34+ +0.72 <0.0001 +0.52 0.0003
SDF-1 −0.26 0.092 0.00 0.98
BFU-E - number of erythrocyte burst-forming units.
CFU-GM - number of granulocyte–macrophage colony-forming units.
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populations. Of note, no correlation was observed be-
tween clonogenic growth and CD45-lin-CD184+ or CD45
+lin-CD184+ CB cells, as well as the GA or SDF-1 plasma
level in preterm infants (Table 5).
The number of circulating progenitor cells firmly depends
on gestational age of the infants
To elucidate whether or not the pool of CB-derived
hematopoietic progenitors determines further develop-
ment of premature complications in infants, we per-
formed univariate and multivariate statistical analyses.
The number of CD133+CD34+ and CD133-CD34+ cells
circulating in CB was higher in preterm infants who
developed RDS, BPD and NEC (Table 3), whereas anemia
was associated only with a higher number of CD133-
CD34+ CB cells. However, multivariate logistic analysis
that was additionally adjusted for GA revealed that the
higher number of CD133+CD34+ and CD133-CD34+
cells in CB is not an independent predictor of any of the
prematurity complications (data not shown).
Finally, to examine the changes in numbers of CSPCs in
blood after birth, we counted the PB-derived progenitors in
the second and sixth week after delivery in both groups of
infants. As shown in Figure 5, the number of CD133+CD34
+ and CD133-CD34+ cells significantly decreased (p< 0.01)
in preterm infants in two and six weeks after delivery,
reaching values similar to those observed in full-term
infants, in whom the number of these cells was stable for
the examined period of time. Since GA of full-term infants
at birth was on average 6.3 weeks greater than that of pre-
term infants (Table 1), the PB taken from preterm babies in
six weeks after delivery corresponds to the same GA as CB
collected from full-term newborns. Thus, the kinetic pro-
files of CD133+CD34+ and CD133-CD34+ CSPCs suggest
that their numbers in CB and PB physiologically decrease
until about the 36th week of GA, and are stable thereafter.Figure 4 Clonogenic growth efficiency of CD34-positive cells obtaine
burst-forming unit-erythroid (BFU-E) or colony-forming unit-granulocyte-mo
counts are expressed in absolute values per 2 × 104 plated cells and repres
group. ***p < 0.001 for comparison between preterm and full-term infantsDiscussion
Preterm delivery is one of the most important factors
of neonatal mortality and morbidity throughout the
world. Recently, the incidence of perinatal death has
considerably decreased as neonatological care has
improved. However, managing morbidity after preterm
labour is still a critical issue [21]. One of the current
major issues in perinatal medicine is the search of valu-
able and early indicators of prematurity complications
onset. Several recent retrospective studies were settled
to find relationship between the blood characteristic
markers or abnormalities and specific prematurity com-
plication or an inflammatory process, however, not al-
ways giving the accurate results [22-25].
During prenatal development, various types of stem
cells migrate, proliferate and differentiate to form tissues
and organs. Tissue and peripheral blood SPCs pools are in
dynamic equilibrium with each other, allowing stem cells
to migrate from extravascular sites or marginal pools into
the circulation and vice versa [26]. Whereas 37–42 weeks
of gestation provide an optimal period of time for and from the CB of 44 preterm or 24 full-term infants. Formation of
nocyte (CFU-GM) was assessed in clonogenic in vitro assays. Colony
ent the median [min–max] from all the performed assays in each
(Mann–Whitney test).
0Figure 5 The number of CD133+CD34+ and CD133-CD34+ blood cells counted in CB at birth as well as in PB two and six weeks after
delivery in 13 preterm and 18 full-term infants. **p < 0.01 for comparison between PB in 2nd and 6th week vs CB. #p < 0.05 for PB in 6th week
vs PB in 2nd week (Mann–Whitney test).
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deeply disturbs normal development. This prospective
study was performed to elucidate the potential cause and
effect relationship between the circulating SC populations
and evolution of premature birth complications.
The absolute numbers of circulating non-HSCs/VSELs
in PB are remarkably low (1–2 cells in 1 μL of blood
under steady-state conditions). Similarly, circulating
HSCs represent a very small fraction of PB cells, and
thus special flow cytometry protocols have to be applied
for identification of those highly restrictive SC popula-
tions [27]. We employed nuclear staining for detection
of NCs present in blood samples and for exclusion of
anucleated cellular debris from further analysis. Such a
defined fraction of small NCs was further analyzed for
CD45 and CD184 antigen expression, therefore two sub-
populations, i.e. CD45–lin–CD184+ non-HSCs/VSELs
and CD45+lin–CD184+ HSCs, could be distinguished
[27]. Receptor CXCR4 (CD184) plays an important role
in the mechanisms of HSCs migration and repopulation,
in regard to the observation, that murine fetuses lacking
this receptor (CXCR4-null model) have multiple defects
that are lethal, including impaired BM hematopoiesis
[28]. Recently, we were able, not only to confirm the
presence of such highly restrictive SCs populations
among blood leukocytes, but also to quantitatively deter-
mine the absolute numbers of these infrequent cells cir-
culating in the blood of patients with various tissue/
organ injuries and disorders [5,6,17]. Of note, the
defined CD45–lin–CD184+ and CD45+lin–CD184+ SC
populations have not been previously evaluated in rela-
tively long-term prospective observation in PB of pre-
term infants.
This study demonstrated for the first time that the num-
ber of primitive non-HSCs circulating in CB is inversely
associated with the birth weight of premature infants. Our
observations imply that during the fetal stage of human
life, primitive, undifferentiated stem cells circulate in theblood in a large number and contribute to organ/tissue
formation. Gradually, the number of non-HSCs decreases
and stabilizes along with the infant’s maturation. The
characteristics of the actually analyzed non-HSCs corres-
pond with very small embryonic-like SCs (VSELs) expres-
sing pluripotent SC markers, described recently in CB by
Kucia et al. [29], with a contribution by our research team.
It has been demonstrated in mice that VSELs reveal pluri-
potency and are able to form all types of mature cells
[30,31]. Furthermore, after the number of molecular ana-
lyses and in vivo experiments performed by Ratajczak
et al., it has been recently proposed that human CB-
derived VSELs correspond to the population of the most
primitive HSCs circulating in the PB [32]. Therefore, if a
small premature infant loses a substantial number of cir-
culating non-HSCs, enriched in VSELs, together with
secundines, this might well have negative clinical conse-
quences for the infant’s development in the long-term. As
we and others have recently reported, VSELs are mobi-
lized in the PB of patients with ischemic stroke, myocar-
dial infarction, or heavy burns, and this increase in the
number of circulating cells is accompanied by elevated
plasma levels of SDF-1 [5-7]. It has been hypothesized that
these cells could attempt to regenerate the damaged tis-
sue. Although we did not observe strict evidence of an
analogous phenomenon in this study, however the num-
ber of non-HSCs/VSELs circulating in PB of premature
infants was significantly greater than in full-term babies
two weeks after delivery. At the same time point, SDF-1
plasma levels in preterm infants were considerably higher
compared to the initial concentration of this chemokine at
premature birth. Noteworthy, we noticed a strong correl-
ation between CB SDF-1 levels and the number of non-
HSCs/VSELs two weeks after delivery. Together, these
observations may suggest that similar pathophysiological
responses observed in stroke patients are noticed in small
premature infants in an attempt to maintain PB-derived
non-HSCs in relatively high concentrations. In order to
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HSCs/VSELs actively support regeneration in the first few
weeks of human life after birth, or whether they remain
largely in a dormant state, further studies are necessary.
However, the differentiation of VSEL-SCs into human
tissue-specific SCs (e.g. hematopoietic or neural) is not en-
tirely elucidated and it is postulated that this process
requires a relatively long period of time [32].
Clearly, the question arises as to whether or not a
number of SCs circulating in CB is associated with the
development of premature birth complications. As a first
step towards addressing this issue, we sought to identify
the highly purified populations of SCs with either dur-
able or limited cause-and-effect relationships. Our
results provide for the first time evidence that the num-
ber of HSCs circulating in CB is the independent pre-
dictor inversely associated with the development of
premature birth complications. These include infections,
anemia, IVH, and RDS, complications associated with
blood and vascular systems origin, the development of
which appears to be conditioned either directly (anemia,
infections) or indirectly (other complications) by HSCs
activity. Hematopoiesis is a complex, hierarchical
process which involves the expansion and differentiation
of a limited number of HSCs into multipotential and
lineage-restricted progenitors, leading to the production
of mature and functional blood cells [33]. HSCs, and
their downstream precursors such as common lymphoid
or myeloid progenitors that possess substantial clono-
genic properties, are able to repopulate the whole me-
dullary and extramedullary hematopoiesis in case of
blood loss that, for example, may occur in case of IVH
in preterm neonates [34]. Similarly, rapid rate of neo-
natal growth is one of the causes of anemia of prematur-
ity that usually occurs during the first or second week of
life in very small preemies. On the other side, iatrogenic
blood loss secondary to sampling of blood for laboratory
tests is nowadays the commonest cause of anemia of
prematurity [35]. Relative but chronic deficiency of
RBCs must be quickly compensated by increased prolif-
erative activity of HSCs to reduce the potential biological
effects of the RBCs scarcity in the body that might result
in or might exaggerate the hypoxia-related complications
in preterm newborns. Similarly, HSCs and their progen-
ies are responsible for proper homeostasis maintenance
of immune cells of myeloid and lymphoid lineage that
protect the newborns against infections during the early
stages of post-natal development. Thus, taken together,
the number of active HSCs determines blood morph-
ology and functions to effectively prevent both anemia
and infections. However, it should be noted that associ-
ation of HSCs with anemia lost significance in multivari-
ate model and severe confounding by gestational age
was observed. Nevertheless, there was no proof for othersuch confounding effects regarding associations of other
complications with HSCs, since the associations retained
statistical significance in multivariate analyses and re-
spective OR values were similar in the uni- and multi-
variate logistic regression models.
What is more, HSCs also influence vascular homeosta-
sis since the endothelial progenitor/precursor cell types
are thought to be derived from the hematopoietic and
vascular systems [36]. The concurrent emergence of
hematopoietic and endothelial precursors in the embry-
onic yolk sac, as well as their overlapping patterns of
gene expression, provides circumstantial evidence for
the derivation of these cell types through a common
progenitor, called hemangioblast, capable of giving rise
to both endothelial and hematopoietic SCs at the earliest
stages of hemato-endothelial differentiation [37]. The
multifaceted modality of hemangioblast progenies, up to
some extent, might be responsible for the fact, that cir-
culating HSCs derived from bone marrow have been
shown to participate in the normal and pathologic post-
natal angiogenesis. Moreover, they were also able to
induce neovascularization when transplanted into ische-
mic tissues [38]. Since, in such indirect way, HSCs could
also correspond to the development of IVH or RDS in
premature infants. As there is at least indirect associ-
ation between vascular dysfunction and pathogenesis of
RDS and IVH, these pathologies might be defined
as ‘vascular-associated’ disorders [39,40].
Furthermore, we showed that the number of HSCs
remains stable for six weeks after birth, the period when
most of the abovementioned complications develop.
This, in turn, at least partly explains the protective effect
of HSCs against prematurity complications, since their
low pool in CB at birth is associated with a long-term
HSC deficit as evidenced by strong correlations between
HSC percentages at birth and six weeks after birth. Of
note, the number of circulating HSCs, unlike the non-
HSCs/VSELs, did not increase in parallel with increased
SDF-1 plasma level, detected two weeks after birth, in
preterm infants. Our finding is similar to the observation
described recently in patients with heavy burns [7]. In
the light of recent reports, the involvement of other fac-
tors including small bioactive lipids that may direct
mobilization and trafficking of SCs, should be also con-
sidered to determine precisely the conditions responsible
for egress and trafficking of CXCR-4 positive HSCs [41].
Indeed, Bowie et al. [42] have recently reported that up
to ~4 weeks post-partum BM-derived HSCs have higher
cell-cycling rates than those from adult BM. They pro-
vide evidence that the chronologically younger HSCs
produce considerable amounts of SDF-1, which stimu-
lates these cells into cycle, and this may reflect the need
for HSCs proliferation or self-renewal during periods of
rapid body growth. Probably, the above observation
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direct association between circulating HSCs counts and
post-natal SDF-1 levels in full-term and preterm infants
found in our study. It is postulated that secretion of con-
siderable amounts of SDF-1, in an autocrine manner by
cycling post-natal HSCs, might interfere with HSC abil-
ity to respond to a chemotactic SDF-1 gradient, and so
impede their trans-marrow trafficking, lodgment and re-
tention in BM niches [42].
To the best of our knowledge, this is the first report
clearly demonstrating that the human HSC population is
associated with certain prematurity complications. Our
results are in accordance with other clinical studies and
suggest an important role of different circulating SC
subpopulations in the development of preterm birth
complications. Likewise, recent findings suggest a pro-
tective role of circulating progenitor cells in respiratory
system disorder found in neonates born prematurely.
The group of Qi et al. observed that RDS survivors had
higher counts of CD34+ progenitor cells compared to
non-survivors. Moreover, they observed that low con-
centrations of circulating CD34+ cells were correlated
with a prolonged duration of mechanical ventilation of
neonates with RDS, which can indicate the disease pro-
gression [43]. In a similar manner, it has recently been
suggested that circulating hematopoietic cells may play
an important vital role in repairing injured tissues and in
disease progression, and thus differential hematopoietic
cell populations may reveal a special paradigm as predic-
tors for human morbidity. Great attention has recently
been given to selected subsets of circulating CD34+ cells
in patients with ischemic heart disease, as these cell
populations might include those involved directly or in-
directly in vascular repair. Likewise, it has been recently
demonstrated that some cells, defined according to the
International Society of Hematotherapy and Graft En-
gineering (ISHAGE) criteria as circulating hematopoietic
progenitor cells (HPCs; CD34+CD45dimVEGFR2- and
CD34+CD45dimCD133+VEGFR2-), were reduced in
patients presenting clinical signs of endothelial dysfunc-
tion, and thus it was postulated that the number of
HPCs might be an independent predictor of morbidity
from cardiovascular diseases and a marker of athero-
sclerotic disease progression [44]. Interestingly, these
results are, to some extent, analogous to our data, in
that the number of highly selected circulating HSCs is
inversely correlated with the risk of the development of
prematurity complications. Altogether, based on the
above-mentioned data, we postulate that analysis of cir-
culating HSC counts may be a valuable predictor for
preterm birth-related morbidity.
A number of different circulating hematopoietic cell
subsets described as CD34-positive cells were recently
shown to be altered in neonates with prematuritycomplications, but without discrimination between more
specific cell phenotype characteristics such as Lin- or
CD184+CD45+ and CD184+CD45- [43,45]. These obser-
vations were confirmed and extended in the present
study. Especially, Lin-CD184+ cells were suggested to be
more immature precursor cells of CD34-positive cells
with a higher potency regarding peripheral tissue repair
mechanisms [46,47]. Finally, in some instances, HSCs
have been shown to contribute to the regeneration of
chronically injured non-hematopoietic tissues. It is inter-
esting to note that, according to recent critical reports,
HSCs neither undergo transdifferentiation into cell types
other than hematopoietic lineage cells nor structurally
contribute to non-hematopoietic tissue regeneration on
a significant scale [48,49]. However, after incorporation
into injured tissue, HSCs might well produce and secrete
humoral factors, creating a conducive microenvironment
which promotes cell chemoattraction, survival and pro-
liferation [50]. Likewise, circulating CB and early post-
natal bone marrow HSCs have been previously reported
not to home to the BM niches and, within the HSCs
engrafting populations, ~95% were in the G0 phase (see
[42] and references therein). These observations suggest
that mobilized HSCs migrate from BM to the peripheral
circulation where they indirectly contribute to organ regen-
eration and help to restore the integrity of extra-marrow
tissues. It is worth noting that HSC transplantation has re-
cently been used extensively for the treatment of numerous
metabolic diseases in children [51]. Because of the variety
of functions of HSCs in the human organism, their precise
role in each disease condition may vary and should be care-
fully examined.
Previous studies have shown that hematopoietic progeni-
tor cells express the CD34 surface antigen [52]. Likewise,
CD34-positive cells represent a functionally primitive
population of progenitor cells that seem to have a higher
cloning efficiency and a very rapid proliferative response to
cytokine stimulation [53]. Moreover, recent studies in bone
marrow have also identified a CD133+ cell population,
which is rare, undergoes self-renewal and differentiation
and might represent stem/progenitor cell population [54].
Thus, we evaluated cell surface expression of CD34 and
CD133 antigens, aiming to characterize the highly hetero-
genic circulating progenitor cell compartment in the blood
of preterm infants and their relation with preterm morbid-
ity. Our results showed that the percentage of CSPCs
detectable in CB was significantly higher in preterm new-
borns compared with full-term fetuses. These results are in
accordance with those of Haneline et al. [55] and Opie
et al. [56], who reported significantly higher numbers of
circulating progenitors in the CB of surviving preterm
infants (23–32 wks of GA) and stillborn fetuses (< 24 wks)
compared with the CB of mature newborns. In addition,
we found that the number of CB-derived CD133+CD34+
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developed prematurity complications such as RDS, BPD
and NEC. Besides, anemia was associated only with a
higher number of CD133-CD34+ CSPCs. However, a statis-
tically significant correlation between the number of
CSPCs and GA was also noticed and the associations of
CSPCs with prematurity complications lost significance in
multivariate analysis adjusted for gestational age.
In the present study, to identify hematopoiesis-related
cells among SPCs circulating in cord blood, clonogenic
assays were employed. Here, we found that the prolifera-
tive potential of BFU-E and CFU-GM was significantly
higher in preterm infants than in full-term infants and
colony numbers positively correlated with the number
of CSPCs in CB. Our findings seem to reproduce the
studies of Opie et al. [56], showing a decreased fre-
quency of clonogenic precursors with advancing gesta-
tional age. This strongly supports the notion that
detected CD133+CD34+ and CD133-CD34+ cells, circu-
lating in CB, determines a strong clonogenic potential of
hematopoietic origin, whereas other examined popula-
tions such as CD45-lin-CD184+ and CD45+lin-CD184+
cells are not directly associated with clonogenicity, what
might indicate their stem derivation and more quiescent
state. Finally, the differences in BFU-E and CFU-GM
numbers between preterm and full-term infants were con-
sistent with differences in the number of CD133+CD34+
and CD133-CD34+ CB cells between these groups
(Table 2). The results obtained strongly indicate that ana-
lyzed subpopulations represent CB-derived hematopoietic
progenitors.
Furthermore, our data seemed to show significant
changes in the numbers of CSPCs in blood after birth.
The number of CD133+CD34+ and CD133-CD34+ cells
in PB gradually decreased during the first six weeks after
birth until the quantities were similar to those detected
in full-term infants. As the observed decrease in the
number of CSPCs runs in parallel with advancing GA
only in the premature infants group, this could indicate
that the quantities of hematopoietic progenitors decrease
physiologically until the 36th week of GA, and are stable
thereafter.
Conclusion
We showed that HSCs circulating in CB, are markedly
associated with the development of premature birth com-
plications. The present findings of the interdependence be-
tween complications related to premature birth and the
number of circulating SCs offer an exciting approach for
further investigations into the pathophysiological processes
underlying the development of the most common prema-
turity disorders. Thus, HSCs ought to be considered as an
attractive and potential target for further research as they
may be relevant for controlling the morbidity of prematureinfants. Efficient prevention and treatment of these condi-
tions remains a priority in medicine. Regardless of further
developments in therapeutic strategies based on improve-
ment of the neonatal care system, the profound under-
standing of pathophysiological mechanisms responsible for
the development of pathological changes in the course of
prematurity complications is particularly important for
their effective treatment. Only a full explanation of all
aspects of this process can contribute to a real improve-
ment in prevention and therapy of such disorders.
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